RNDr. Petr Chlapek, DiS., Ph.D.
Assistant professor, Section of Genetics and Molecular Biology
office: bldg. C13/316
Kamenice 753/5
625 00 Brno
phone: | +420 549 49 3970 |
---|---|
e‑mail: |
Total number of publications: 46
2022
-
Serotonin limits generation of chromaffin cells during adrenal organ development
Nature Communications, year: 2022, volume: 13, edition: 1, DOI
-
Thiosemicarbazones and selected tyrosine kinase inhibitors synergize in pediatric solid tumors: NDRG1 upregulation and impaired prosurvival signaling in neuroblastoma cells
Frontiers in Pharmacology, year: 2022, volume: 13, edition: September, DOI
-
Thiosemicarbazones Can Act Synergistically with Anthracyclines to Downregulate CHEK1 Expression and Induce DNA Damage in Cell Lines Derived from Pediatric Solid Tumors
International Journal of Molecular Sciences, year: 2022, volume: 23, edition: 15, DOI
2021
-
A selective p53 activator and anticancer agent to improve colorectal cancer therapy
Cell Reports, year: 2021, volume: 35, edition: 2, DOI
2020
-
Novel Thiosemicarbazones Sensitize Pediatric Solid Tumor Cell-Types to Conventional Chemotherapeutics through Multiple Molecular Mechanisms
Cancers, year: 2020, volume: 12, edition: 12, DOI
-
Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: A Focus on Transporters and Lysosomal Sequestration
International Journal of Molecular Sciences, year: 2020, volume: 21, edition: 9, DOI
2019
-
Comparative Analysis of Putative Prognostic and Predictive Markers in Neuroblastomas: High Expression of PBX1 Is Associated With a Poor Response to Induction Therapy
Frontiers in Oncology, year: 2019, volume: 9, edition: NOV 15, DOI
-
New inhibitor of the TAp73 interaction with MDM2 and mutant p53 with promising antitumor activity against neuroblastoma
Cancer Letters, year: 2019, volume: 446, edition: 4, DOI
-
Prediction of neuroblastoma cell response to treatment with natural or synthetic retinoids using selected protein biomarkers
PLOS ONE, year: 2019, volume: 14, edition: 6, DOI
2018
-
Traffic lights for retinoids in oncology: molecular markers of retinoid resistance and sensitivity and their use in the management of cancer differentiation therapy
BMC Cancer, year: 2018, volume: 18, edition: 1059, DOI